LCN2 and osteosarcoma: Conclusively, human osteosarcoma HOS and U2OS cell-derived LCN2 contributes to inhibition of cellular migration through the MEK–ERK signaling pathway to downstream MET, and these findings imply an identified biomarker of LCN2 on anti-metastasis of osteosarcoma.